- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05979727
Dose-finding PKPD Trial for RE02 in Healthy Subjects
November 20, 2023 updated by: Reconnect Labs
Double-blind, Randomized, Dose-response Study of RE02 in Healthy Subjects
The goal of this clinical trial is to compare corresponding inter- and intraindividual pharmacokinetic and pharmacodynamic profiles including assessments of safety & tolerability of three different doses against a placebo control.
Study Overview
Detailed Description
Participants will undergo a series of four study days with varying doses of RE02 and a placebo.
The intervention is embedded in controlled environment and continuous psychological support.
Pharmacokinetic and pharmacodynamic assessments are obtained over the course of 6 hours on each study visit to estimate dose-exposure relationship and drug-drug-interaction.
Additionally, the occurrence of adverse events will be closely monitored throughout the whole study.
Study Type
Interventional
Enrollment (Estimated)
15
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Robin von Rotz
- Phone Number: +41797990831
- Email: robin@reconnect-labs.com
Study Locations
-
-
ZH
-
Zürich, ZH, Switzerland, 8032
- Recruiting
- University Hospital of Psychiatry Zurich
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Willing and capable to give informed consent for the participation in the study after it has been thoroughly explained
- Willing to refrain from drinking alcohol one day before testing days and caffeinated drinks at the testing days and from consuming psychoactive substances or other medications for 2 weeks before testing days and for the duration of the study
- Already experienced with psychedelic substances (at least 5 prior experiences - microdoses do not count)
- Able and willing to comply with all study requirements
- Informed consent form was signed
- Good knowledge of the German language
- Participant informs study physicians / project scientists about simultaneous treatment or therapy with other physicians and about current intake of psychotropic substances or medication
- Women of childbearing potential are required to use effective, established contraception, such as oral, injected or implanted hormonal methods of contraception, placement of an intrauterine device (IUD) or intrauterine system (IUS), barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository
Exclusion Criteria:
- Previous significant adverse response to a hallucinogenic drug
- Participation in another study where pharmaceutical compounds will be given
- Presence of Axis I affective, anxiety, or dissociative disorders
- Present or antecedent diagnosis of bipolar disorder (I, II, not otherwise specified), schizophrenia, schizoaffective disorder, psychosis, or other disorders from the psychotic spectrum
- First-degree relatives with present or antecedent schizophrenia, schizoaffective disorder, or bipolar disorder type I
- History of head trauma, seizures, cancer, or cerebrovascular accidents
- Recent cardiac or brain surgery
- Current abuse of medication or psychotropic substances (including nicotine addiction) according to SCID I criteria
- Presence of major internal or neurological disorders (including sepsis, pheochromocytoma, thyrotoxicosis, drug-induced fibrosis, familiar or basilar artery migraine)
- Cardiovascular disease (hypertonia, coronary artery disease, heart insufficiency, myocardical infarction, coronary spastic angina)
- Peripheral vascular disease (thromboangiitis obliterans, luetic arteritis, severe arteriosclerosis, thrombophlebitis, Raynaud's disease)
- Cerebrovascular disease (e.g., stroke, intracranial bleeding / hemorrhage, intracranial aneurysm)
- Serious abnormalities in ECG or blood count/chemistry
- Liver or renal or pulmonary disease
- Current use of medications with significant interaction potential with MAOI (e.g., antidepressants, antipsychotics, psychostimulants, dopaminergic/serotonergic agents, anticonvulsants)
- high risk of adverse emotional or behavioral reaction based on investigator's clinical evaluation (e.g., evidence of serious personality disorder, serious current stressors, lack of social support)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Placebo Comparator
|
Active Comparator: Low dose of RE02
|
Low, medium or high dose of RE02
|
Active Comparator: Moderate dose of RE02
|
Low, medium or high dose of RE02
|
Active Comparator: High dose of RE02
|
Low, medium or high dose of RE02
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetic parameter "Cmax"
Time Frame: Changes from baseline to study days 1,2,3,4
|
Dose-dependent changes in Cmax of several doses of RE02
|
Changes from baseline to study days 1,2,3,4
|
Pharmacokinetic parameter "Area under the curve (AUC)"
Time Frame: Changes from baseline to study days 1,2,3,4
|
Dose-dependent changes in AUC of several doses of RE02.
|
Changes from baseline to study days 1,2,3,4
|
Pharmacokinetic parameter "T1/2"
Time Frame: Changes from baseline to study days 1,2,3,4
|
Dose-dependent changes in T1/2 of several doses of RE02.
|
Changes from baseline to study days 1,2,3,4
|
Incidence of Treatment-Emergent Adverse Events
Time Frame: On study days 1,2,3,4
|
Dose-dependent changes in incidence of adverse drug reactions
|
On study days 1,2,3,4
|
Blood count (Lab biochemistry)
Time Frame: Changes from baseline to End of Study, an average of 4 weeks
|
Changes from baseline in blood count
|
Changes from baseline to End of Study, an average of 4 weeks
|
Clinical chemistry (Lab biochemistry)
Time Frame: Changes from baseline to End of Study, an average of 4 weeks
|
Changes from baseline in any clinical chemistry parameter with potential clinical relevance.
|
Changes from baseline to End of Study, an average of 4 weeks
|
Blood coagulation (Lab biochemistry)
Time Frame: Changes from baseline to End of Study, an average of 4 weeks
|
Changes from baseline in blood coagulation
|
Changes from baseline to End of Study, an average of 4 weeks
|
QT interval (12-lead Electrocardiogram [ECG])
Time Frame: Changes from baseline to study days 1,2,3,4
|
Dose-dependent changes of QT intervals assessed by clinical 12-lead ECG)
|
Changes from baseline to study days 1,2,3,4
|
Blood pressure
Time Frame: Changes from baseline to study days 1,2,3,4
|
Dose-dependent changes in systolic and diastolic blood pressure
|
Changes from baseline to study days 1,2,3,4
|
Heart rate
Time Frame: Changes from baseline to study days 1,2,3,4
|
Dose-dependent changes in heart rate
|
Changes from baseline to study days 1,2,3,4
|
Temperature
Time Frame: Changes from baseline to study days 1,2,3,4
|
Dose-dependent changes in temperature
|
Changes from baseline to study days 1,2,3,4
|
Subjective effects
Time Frame: Changes from baseline to study days 1,2,3,4
|
Dose-dependent changes in trajectories of subjective effects
|
Changes from baseline to study days 1,2,3,4
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Erich Seifritz, Prof, University Hospital of Psychiatry Zurich
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 20, 2023
Primary Completion (Estimated)
December 1, 2023
Study Completion (Estimated)
January 1, 2024
Study Registration Dates
First Submitted
July 31, 2023
First Submitted That Met QC Criteria
July 31, 2023
First Posted (Actual)
August 7, 2023
Study Record Updates
Last Update Posted (Estimated)
November 22, 2023
Last Update Submitted That Met QC Criteria
November 20, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Other Study ID Numbers
- MEO-DMT-VR
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
No plan available to date.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Manitol
-
National Institute of Pediatrics, MexicoHospital Infantil de Mexico Federico GomezTerminated
-
University Hospital, Basel, SwitzerlandCompletedHealthy | Substance-related Disorder | Mood DisorderSwitzerland
-
University Hospital, Basel, SwitzerlandCompleted